Filing Details

Accession Number:
0001209191-19-056373
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-11-13 16:30:44
Reporting Period:
2019-11-08
Accepted Time:
2019-11-13 16:30:44
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1123494 Harvard Bioscience Inc HBIO Laboratory Analytical Instruments (3826) 043306140
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1197452 Bertrand Loy C/o Harvard Bioscience, Inc.
84 October Hill Rd.
Holliston MA 01746
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-11-08 6,616 $2.64 163,959 No 4 P Direct
Common Stock Acquisiton 2019-11-11 12,855 $2.59 176,814 No 4 P Direct
Common Stock Acquisiton 2019-11-12 10,579 $2.51 187,393 No 4 P Direct
Common Stock Acquisiton 2019-11-13 6,100 $2.52 193,493 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
No 4 P Direct
No 4 P Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 68,466 Indirect by The BZH Trust
Footnotes
  1. This transaction was executed in multiple trades at prices ranging from $2.52 to $2.75, inclusive. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  2. Includes (a) a deferred stock award of 3,300 restricted stock units which vests in full on December 31, 2019; (b) a deferred stock award of 35,100 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 16, 2019, immediately prior to the commencement of such meeting, and (ii) May 23, 2020; (c) a deferred stock award of 3,500 restricted stock units which vests in full on December 31, 2019; and (d) 122,059 shares of common stock held by the Reporting Person
  3. This transaction was executed in multiple trades at prices ranging from $2.57 to $2.70, inclusive. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  4. Includes the awards referenced in clauses (a) through (c) of footnote (2) above, plus 134,914 shares of common stock held by the Reporting Person.
  5. This transaction was executed in multiple trades at prices ranging from $2.49 to $2.58, inclusive. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  6. Includes the awards referenced in clauses (a) through (c) of footnote (2) above, plus 145,493 shares of common stock held by the Reporting Person.
  7. This transaction was executed in multiple trades at prices ranging from $2.48 to $2.54, inclusive. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  8. Includes the awards referenced in clauses (a) through (c) of footnote (2) above, plus 151,593 shares of common stock held by the Reporting Person.